Waystar Weighs Sale Options Amid Market Challenges
Healthcare software firm Waystar is exploring a potential sale, two years after going public.
Waystar, a healthcare software company known for its technology that automates administrative tasks for hospitals and doctors, is considering a range of strategic options, including a possible sale. According to seven sources familiar with the matter, the company could return to private ownership just two years after its initial public offering in New York.
Investment Bank Evercore Advising
Waystar has engaged investment bank Evercore to guide the process, which remains in its preliminary stages. Sources, who spoke under the condition of anonymity due to the confidential nature of the discussions, indicated that the outcome is uncertain and a sale may not ultimately happen. Both Waystar and Evercore declined to comment on the situation.
Market Context and Shareholder Impact
The company's market value has dropped to approximately $4.8 billion following a 24% decline in its share price this year, part of a wider downturn in the software sector. Analysts from Morgan Stanley have pointed out that investor concerns about the impact of artificial intelligence on software companies have contributed to the pressure on Waystar's stock, which had peaked at $45 in 2025 after debuting at $20.
Waystar's largest stakeholders include EQT with a 13% share, the Canada Pension Plan Investment Board (CPPIB) with 10%, and BlackRock Institutional Trust Company with 8%. EQT and BlackRock have declined to comment, while CPPIB has not yet responded to requests for comment.
Company Background and Strategic Positioning
Formed in 2017 through the merger of Zirmed and Navicure, Waystar has sought to establish itself as a healthcare technology leader, emphasizing its software solutions over traditional service-based models. This positioning aimed to attract higher valuations typically associated with tech firms. Despite initial investor enthusiasm, the company now faces market skepticism, particularly regarding the evolving AI landscape.
The current exploration of options, including a potential auction, could test whether investor interest in software companies is on the rebound. Waystar's strategic choices will be closely watched as they could signal broader trends in the healthcare technology sector.